ELOVL2 is a novel tumor suppressor attenuating tamoxifen resistance in breast cancer via suppressing the AKT pathway [gene expression]

Analysis of tamoxifen-sensitivity recovery effect by genes which are regulated by ELOVL2(Elongation of very long chain fatty acids protein 2) at gene expression level in breast cancer. This study identifies that ELOVL2 regulates AKT or ER signaling-related genes and ELOVL2 as an essential gene responsible for resistance. Total RNA obtained from tamoxifen-resistant MCF-7(Tam-R MCF-7) where ELOVL2 was overexpressed